{"title_page": "Applied Genetic Technologies Corporation", "text_new": "{{Multiple issues|\n{{news release|1=article|date=October 2017}}\n{{notability|Companies|date=October 2017}} }}\n{{Infobox company\n| name             = Applied Genetic Technologies Corporation\n| logo             = File:Applied Genetic Technologies Corporation logo.png\n| type             = [[Public company]]\n| industry         = [[Biotechnology]]\n| traded_as        = {{NASDAQ|AGTC}}<br>[[Russell Microcap Index]] component\n| founded          = {{start date and age|1999|01|19}}\n| location         = [[Alachua, Florida]], United States\n| key_people       = {{ubl|class=nowrap|Susan B. Washer|{{small|(President & CEO)}}|William A. Sullivan|{{small|(CFO)}}}}\n| revenue          = {{ubl|class=nowrap|{{decrease}} US$ 24.19 million|{{small|(FY JUN 30, 2018)}}}}\n| operating_income = {{ubl|class=nowrap|{{decrease}} US$ -22.38 million|{{small|(FY JUN 30, 2018)}}}}\n| net_income       = {{ubl|class=nowrap|{{decrease}} US$ -21.30 million|{{small|(FY JUN 30, 2018)}}}}\n| assets           = {{ubl|class=nowrap|{{decrease}} US$ 118.53 million|{{small|(FY JUN 30, 2018)}}}}\n| equity           = {{ubl|class=nowrap|{{decrease}} US$ 99.18 million|{{small|(FY JUN 30, 2018)}}}}\n| num_employees    = {{ubl|class=nowrap|78|{{small|(FY JUN 30, 2018)}}}}\n| website          = {{URL|https://www.agtc.com/|AGTC.com}}\n| footnotes        = <ref name=10K2018>{{cite web|url=https://www.sec.gov/Archives/edgar/data/1273636/000156459018022913/agtc-10k_20180630.htm|title=US SEC: Form 10-K Applied Genetic Technologies Corporation|publisher=[[U.S. Securities and Exchange Commission]]|date=September 11, 2018|accessdate=December 1, 2018}}</ref>\n}}\n\nThe '''Applied Genetic Technologies Corporation''' is a publicly traded ({{NASDAQ|AGTC}})<ref>{{cite web|title=Applied Genetic Technologies Corporation (AGTC)|url=http://www.nasdaq.com/symbol/agtc|website=NASDAQ.com|accessdate=4 January 2016}}</ref> biotechnology company that is part of the [[NASDAQ Biotechnology Index]]. It was founded in 1999 and has its headquarters in [[Alachua, Florida]].<ref name=\"bberg\">{{cite web |url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=7604030 |title=Company Overview of Applied Genetic Technologies Corporation |publisher=[[Bloomberg L.P.|Bloomberg]] |accessdate=November 15, 2016}}</ref> In late June 2019, the company announced the appointment of Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah, M.D., M.B.A., to Join as Chief Medical Officer.<ref>{{Cite web|url=http://ir.agtc.com/news-releases/news-release-details/agtc-announces-new-leadership-appointments|title=AGTC Announces New Leadership Appointments|website=Applied Genetic Technologies Corporation|language=en|access-date=2020-03-26}}</ref>\n\nThe company focuses on ophthalmologic genetic diseases. The company's technologies are aimed at products that might have the potential to treat   [[achromatopsia]], [[Retinoschisis|X-linked retinoschisis]],<ref>{{cite web|last1=Chen|first1=Angela|title=Biogen to Pay Applied Genetic $124 Million to Develop Eye-Disease Treatments|url=https://www.wsj.com/articles/biogen-to-pay-applied-genetic-124-million-to-develop-eye-disease-treatments-1435855591|website=Wall Street Journal|accessdate=4 January 2016}}</ref><ref>{{cite web|title=AGTC Announces Data Evaluating the Natural History of Patients With X-Linked Retinoschisis at the 48th Annual Retina Society Meeting|url=https://finance.yahoo.com/news/agtc-announces-data-evaluating-natural-110100359.html|website=Yahoo Finance|accessdate=4 January 2016}}{{dead link|date=October 2017}}</ref> X-linked [[retinitis pigmentosa]],<ref>{{cite web|title=Biogen enters eye-treatment arena with AGTC deal|url=https://www.reuters.com/article/us-biogen-agtc-idUSKCN0PC1KR20150702|website=Reuters|accessdate=4 January 2016|date=2 July 2015}}</ref> and [[age-related macular degeneration]].<ref>{{cite web|last1=Ballie|first1=Katherine|title=Penn-Michigan State Team Develops Novel Gene Therapy for Achromatopsia|url=http://www.upenn.edu/pennnews/news/penn-michigan-state-team-develops-novel-gene-therapy-achromatopsia|website=www.upenn.edu|accessdate=4 January 2016}}</ref>  The company has six products in various stages of development; as of 2016, none had yet been approved.<ref>{{cite web|title=Finding Cures for Visual Disorders l Products|url=http://www.agtc.com/products|website=www.agtc.com|accessdate=4 January 2016|archive-url=https://web.archive.org/web/20160105124602/http://www.agtc.com/products|archive-date=5 January 2016|url-status=dead}}</ref>\n\nIn January 2017, AGTC entered into a strategic research and development collaboration with Bionic Sight, an innovator in the emerging field of [[optogenetics]] and retinal coding. Through the collaboration, AGTC and Bionic Sight will to develop a new optogenetic therapy that leverages AGTC\u2019s deep experience in gene therapy and ophthalmology.<ref>{{Cite web|url=https://agtc.com/about/collaborations/|title=Collaborations|website=agtc.com|access-date=2020-03-13}}</ref>\n\nOn January 9, 2020, the company reported positive results from a Phase 1/2 trial for its investigational [[gene therapy]] for [[retinitis]] pigmentosa.<ref>{{Cite web|url=https://www.marketwatch.com/story/applied-genetic-technologies-stock-rockets-on-early-stage-eye-therapy-data-2020-01-09|title=Applied Genetic Technologies' stock rockets on early-stage eye therapy data|last=Lee|first=Jaimy|website=MarketWatch|language=en-US|access-date=2020-02-25}}</ref>\u00a0A few weeks later, the company reported interim six-month data from the [[Dose-escalation study|dose-escalation]] cohorts of its ongoing Phase 1/2 clinical programs in patients with [[achromatopsia]] due to mutation in the ACHM CNGB3 or ACHM CNGA3 genes.<ref>{{Cite web|url=http://ir.agtc.com/news-releases/news-release-details/agtc-reports-encouraging-interim-six-month-data-dose-escalation|title=AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1/2 Clinical Trials in Achromatopsia|website=Applied Genetic Technologies Corporation|language=en|access-date=2020-03-04}}</ref> Applied Genetic Technologies Corporation is a patient partner within the blinding eye disease and rare disease community, including organizations like Foundation for Fighting Blindness and Global Genes.<ref>{{Cite web|url=https://agtc.com/patients/patient-partners/|title=Patient Partners|website=agtc.com|access-date=2020-04-02}}</ref> \n\n==References==\n{{Reflist}}\n\n==External links==\n* [http://www.agtc.com/ Official website]\n* {{Finance links|name = AGTC|symbol = AGTC|sec_cik = AGTC|yahoo = AGTC|google = AGTC|bloomberg = AGTC:US}}\n\n[[Category:Ophthalmology organizations]]\n[[Category:Biotechnology companies established in 1999]]\n[[Category:1999 establishments in Florida]]\n[[Category:Companies listed on NASDAQ]]\n\n\n{{US-company-stub}}\n", "text_old": "{{Multiple issues|\n{{news release|1=article|date=October 2017}}\n{{notability|Companies|date=October 2017}} }}\n{{Infobox company\n| name             = Applied Genetic Technologies Corporation\n| logo             = File:Applied Genetic Technologies Corporation logo.png\n| type             = [[Public company]]\n| industry         = [[Biotechnology]]\n| traded_as        = {{NASDAQ|AGTC}}<br>[[Russell Microcap Index]] component\n| founded          = {{start date and age|1999|01|19}}\n| location         = [[Alachua, Florida]], United States\n| key_people       = {{ubl|class=nowrap|Susan B. Washer|{{small|(President & CEO)}}|William A. Sullivan|{{small|(CFO)}}}}\n| revenue          = {{ubl|class=nowrap|{{decrease}} US$ 24.19 million|{{small|(FY JUN 30, 2018)}}}}\n| operating_income = {{ubl|class=nowrap|{{decrease}} US$ -22.38 million|{{small|(FY JUN 30, 2018)}}}}\n| net_income       = {{ubl|class=nowrap|{{decrease}} US$ -21.30 million|{{small|(FY JUN 30, 2018)}}}}\n| assets           = {{ubl|class=nowrap|{{decrease}} US$ 118.53 million|{{small|(FY JUN 30, 2018)}}}}\n| equity           = {{ubl|class=nowrap|{{decrease}} US$ 99.18 million|{{small|(FY JUN 30, 2018)}}}}\n| num_employees    = {{ubl|class=nowrap|78|{{small|(FY JUN 30, 2018)}}}}\n| website          = {{URL|https://www.agtc.com/|AGTC.com}}\n| footnotes        = <ref name=10K2018>{{cite web|url=https://www.sec.gov/Archives/edgar/data/1273636/000156459018022913/agtc-10k_20180630.htm|title=US SEC: Form 10-K Applied Genetic Technologies Corporation|publisher=[[U.S. Securities and Exchange Commission]]|date=September 11, 2018|accessdate=December 1, 2018}}</ref>\n}}\n\nThe '''Applied Genetic Technologies Corporation''' is a publicly traded ({{NASDAQ|AGTC}})<ref>{{cite web|title=Applied Genetic Technologies Corporation (AGTC)|url=http://www.nasdaq.com/symbol/agtc|website=NASDAQ.com|accessdate=4 January 2016}}</ref> biotechnology company that is part of the [[NASDAQ Biotechnology Index]]. It was founded in 1999 and has its headquarters in [[Alachua, Florida]].<ref name=\"bberg\">{{cite web |url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=7604030 |title=Company Overview of Applied Genetic Technologies Corporation |publisher=[[Bloomberg L.P.|Bloomberg]] |accessdate=November 15, 2016}}</ref> In late June 2019, the company announced the appointment of Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah, M.D., M.B.A., to Join as Chief Medical Officer.<ref>{{Cite web|url=http://ir.agtc.com/news-releases/news-release-details/agtc-announces-new-leadership-appointments|title=AGTC Announces New Leadership Appointments|website=Applied Genetic Technologies Corporation|language=en|access-date=2020-03-26}}</ref>\n\nThe company focuses on ophthalmologic genetic diseases. The company's technologies are aimed at products that might have the potential to treat   [[achromatopsia]], [[Retinoschisis|X-linked retinoschisis]],<ref>{{cite web|last1=Chen|first1=Angela|title=Biogen to Pay Applied Genetic $124 Million to Develop Eye-Disease Treatments|url=https://www.wsj.com/articles/biogen-to-pay-applied-genetic-124-million-to-develop-eye-disease-treatments-1435855591|website=Wall Street Journal|accessdate=4 January 2016}}</ref><ref>{{cite web|title=AGTC Announces Data Evaluating the Natural History of Patients With X-Linked Retinoschisis at the 48th Annual Retina Society Meeting|url=https://finance.yahoo.com/news/agtc-announces-data-evaluating-natural-110100359.html|website=Yahoo Finance|accessdate=4 January 2016}}{{dead link|date=October 2017}}</ref> X-linked [[retinitis pigmentosa]],<ref>{{cite web|title=Biogen enters eye-treatment arena with AGTC deal|url=https://www.reuters.com/article/us-biogen-agtc-idUSKCN0PC1KR20150702|website=Reuters|accessdate=4 January 2016|date=2 July 2015}}</ref> and [[age-related macular degeneration]].<ref>{{cite web|last1=Ballie|first1=Katherine|title=Penn-Michigan State Team Develops Novel Gene Therapy for Achromatopsia|url=http://www.upenn.edu/pennnews/news/penn-michigan-state-team-develops-novel-gene-therapy-achromatopsia|website=www.upenn.edu|accessdate=4 January 2016}}</ref>  The company has six products in various stages of development; as of 2016, none had yet been approved.<ref>{{cite web|title=Finding Cures for Visual Disorders l Products|url=http://www.agtc.com/products|website=www.agtc.com|accessdate=4 January 2016|archive-url=https://web.archive.org/web/20160105124602/http://www.agtc.com/products|archive-date=5 January 2016|url-status=dead}}</ref>\n\nIn January 2017, AGTC entered into a strategic research and development collaboration with Bionic Sight, an innovator in the emerging field of [[optogenetics]] and retinal coding. Through the collaboration, AGTC and Bionic Sight will to develop a new optogenetic therapy that leverages AGTC\u2019s deep experience in gene therapy and ophthalmology.<ref>{{Cite web|url=https://agtc.com/about/collaborations/|title=Collaborations|website=agtc.com|access-date=2020-03-13}}</ref>\n\nOn January 9, 2020, the company reported positive results from a Phase 1/2 trial for its investigational [[gene therapy]] for [[retinitis]] pigmentosa.<ref>{{Cite web|url=https://www.marketwatch.com/story/applied-genetic-technologies-stock-rockets-on-early-stage-eye-therapy-data-2020-01-09|title=Applied Genetic Technologies' stock rockets on early-stage eye therapy data|last=Lee|first=Jaimy|website=MarketWatch|language=en-US|access-date=2020-02-25}}</ref>\u00a0A few weeks later, the company reported interim six-month data from the [[Dose-escalation study|dose-escalation]] cohorts of its ongoing Phase 1/2 clinical programs in patients with [[achromatopsia]] due to mutation in the ACHM CNGB3 or ACHM CNGA3 genes.<ref>{{Cite web|url=http://ir.agtc.com/news-releases/news-release-details/agtc-reports-encouraging-interim-six-month-data-dose-escalation|title=AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1/2 Clinical Trials in Achromatopsia|website=Applied Genetic Technologies Corporation|language=en|access-date=2020-03-04}}</ref> \n\n==References==\n{{Reflist}}\n\n==External links==\n* [http://www.agtc.com/ Official website]\n* {{Finance links|name = AGTC|symbol = AGTC|sec_cik = AGTC|yahoo = AGTC|google = AGTC|bloomberg = AGTC:US}}\n\n[[Category:Ophthalmology organizations]]\n[[Category:Biotechnology companies established in 1999]]\n[[Category:1999 establishments in Florida]]\n[[Category:Companies listed on NASDAQ]]\n\n\n{{US-company-stub}}\n", "name_user": "Kristindemauro", "label": "safe", "comment": "added a sentence about AGTC patient partner initiative", "url_page": "//en.wikipedia.org/wiki/Applied_Genetic_Technologies_Corporation"}
